Zai-Yuan Ye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zai-Yuan Ye has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
Qin-Shu Shao
14 shared publicationsYuan-Shui Sun
10 shared publicationsYuan-Yu Wang
7 shared publicationsQiong Yang
General Surgery, Cancer Center, Department of Breast Surgery, Affiliated People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, 310014, China
6 shared publications- Zhong-Sheng Zhao
Zhejiang Provincial People’s Hospital
6 shared publications Ji Xu
5 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Molecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study
Lynch syndrome (LS) is an inherited disorder caused by germline mutations in mismatch repair (MMR) genes or EPCAM deletions and is primarily associated with an increased risk of gastrointestinal and endometrial cancers. However, LS-associated gliomas are rare, and their clinical and molecular characteristics remain poorly defined. The objective of this study was to systematically characterize the prevalence, genetic landscape, molecular features, and clinical outcomes of LS-associated gliomas. We retrospectively analyzed a multicenter cohort of 5,594 glioma patients who underwent targeted next-generation sequencing to identify pathogenic germline mutations in LS-associated genes. Clinical characteristics, molecular features, treatment histories, and outcomes of LS-associated glioma patients were systematically evaluated and compared with those of LS-associated colorectal cancer (CRC) patients. Among 5,594 glioma patients, 54 individuals (0.97%) were identified as carrying pathogenic germline LS-associated mutations, with a median age of 37.9 years. High-grade gliomas accounted for 68.5% (37/54) of cases, while 9.3% (5/54) were low-grade gliomas. Mutations in MSH2 and MSH6 were predominant, showing a distribution distinct from that observed in LS-associated colorectal cancer (CRC). Compared with LS CRC patients, LS-associated glioma patients exhibited significantly lower frequencies of high tumor mutational burden (TMB-H), microsatellite instability–high (MSI-H), and PD-L1 positivity, indicating unique molecular characteristics. Treatment history analysis showed that LS glioma patients generally responded well to temozolomide treatment, although those harboring MSH2 mutations had a worse prognosis. A family history of cancer was reported in 16.7% (9/54) of LS glioma patients. This study provides a comprehensive characterization of the prevalence, molecular landscape, and clinical outcomes of LS-associated gliomas. The distinct molecular features and prognostic implications identified herein may facilitate improved recognition and inform more personalized management strategies for this rare patient population. The online version contains supplementary material available at 10.1186/s12967-026-08119-9. The online version contains supplementary material available at 10.1186/s12967-026-08119-9.
- 15 April 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessMolecular and clinical characteristics of glioma patients with germline pathogenic mutations of Lynch syndrome genes: a large-scale multicenter study
Lynch syndrome (LS) is an inherited disorder caused by germline mutations in mismatch repair (MMR) genes or EPCAM deletions and is primarily associated with an increased risk of gastrointestinal and endometrial cancers. However, LS-associated gliomas are rare, and their clinical and molecular characteristics remain poorly defined. The objective of this study was to systematically characterize the prevalence, genetic landscape, molecular features, and clinical outcomes of LS-associated gliomas. We retrospectively analyzed a multicenter cohort of 5,594 glioma patients who underwent targeted next-generation sequencing to identify pathogenic germline mutations in LS-associated genes. Clinical characteristics, molecular features, treatment histories, and outcomes of LS-associated glioma patients were systematically evaluated and compared with those of LS-associated colorectal cancer (CRC) patients. Among 5,594 glioma patients, 54 individuals (0.97%) were identified as carrying pathogenic germline LS-associated mutations, with a median age of 37.9 years. High-grade gliomas accounted for 68.5% (37/54) of cases, while 9.3% (5/54) were low-grade gliomas. Mutations in MSH2 and MSH6 were predominant, showing a distribution distinct from that observed in LS-associated colorectal cancer (CRC). Compared with LS CRC patients, LS-associated glioma patients exhibited significantly lower frequencies of high tumor mutational burden (TMB-H), microsatellite instability–high (MSI-H), and PD-L1 positivity, indicating unique molecular characteristics. Treatment history analysis showed that LS glioma patients generally responded well to temozolomide treatment, although those harboring MSH2 mutations had a worse prognosis. A family history of cancer was reported in 16.7% (9/54) of LS glioma patients. This study provides a comprehensive characterization of the prevalence, molecular landscape, and clinical outcomes of LS-associated gliomas. The distinct molecular features and prognostic implications identified herein may facilitate improved recognition and inform more personalized management strategies for this rare patient population. The online version contains supplementary material available at 10.1186/s12967-026-08119-9. The online version contains supplementary material available at 10.1186/s12967-026-08119-9.
- Top Cited PapersOpen Access
- 5 January 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
The regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism
The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.
- 5 January 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Top Cited PapersOpen AccessThe regulatory roles and therapeutic strategies of the solute carrier transporters in cancer metabolism
The Solute Carrier (SLC) family regulates cancer metabolism, supporting proliferation and immune evasion. Key members, such as GLUT1, LAT1, ASCT2, xCT and MCT4, drive metabolic reprogramming and are therapeutic targets. Selective inhibitors like BAY-876 show preclinical efficacy. Combining SLC inhibition with standard therapies may overcome resistance, while personalized strategies and advances in biomarkers and drug delivery are critical for clinical translation.
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9418012
E2F4 Mediates Mitophagy to Inhibit Ferroptosis in Esophageal Cancer Cells by Activating GPR176
Esophageal cancer (EC) is driven by complex dysregulated molecular networks, and ferroptosis—an iron‐dependent, non‐apoptotic form of regulated cell death—has emerged as a critical modulator of tumorigenesis. However, the functional contribution and mechanistic basis of GPR176 in ferroptosis regulation during EC progression remain largely unexplored. Here, we integrated computational and experimental approaches to delineate the role of GPR176 and its upstream regulator E2F4 in EC ferroptosis. Bioinformatic analysis revealed consistent upregulation of both GPR176 and E2F4 in EC tissues, which was further confirmed by molecular validation. Functional assays demonstrated that GPR176 overexpression conferred resistance to ferroptosis in EC cells, as reflected by reduced malondialdehyde, intracellular Fe 2+ , and lipid reactive oxygen species (ROS) accumulation, alongside altered expression of core ferroptosis mediators. This protective effect was associated with the suppression of mitophagy, as indicated by alterations in mitochondrial function and autophagy‐related markers. Mechanistically, we demonstrated that E2F4 directly binds to the GPR176 promoter and transcriptionally activates its expression. Rescue experiments further validated that GPR176 overexpression abrogated the enhanced mitophagy and ferroptosis induced by E2F4 depletion. Collectively, our findings define an E2F4/GPR176/mitophagy axis that acts to suppress ferroptosis in EC, highlighting this pathway as a novel therapeutic target for inducing ferroptosis in EC intervention.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1) , 9418012
Open AccessE2F4 Mediates Mitophagy to Inhibit Ferroptosis in Esophageal Cancer Cells by Activating GPR176
Esophageal cancer (EC) is driven by complex dysregulated molecular networks, and ferroptosis—an iron‐dependent, non‐apoptotic form of regulated cell death—has emerged as a critical modulator of tumorigenesis. However, the functional contribution and mechanistic basis of GPR176 in ferroptosis regulation during EC progression remain largely unexplored. Here, we integrated computational and experimental approaches to delineate the role of GPR176 and its upstream regulator E2F4 in EC ferroptosis. Bioinformatic analysis revealed consistent upregulation of both GPR176 and E2F4 in EC tissues, which was further confirmed by molecular validation. Functional assays demonstrated that GPR176 overexpression conferred resistance to ferroptosis in EC cells, as reflected by reduced malondialdehyde, intracellular Fe 2+ , and lipid reactive oxygen species (ROS) accumulation, alongside altered expression of core ferroptosis mediators. This protective effect was associated with the suppression of mitophagy, as indicated by alterations in mitochondrial function and autophagy‐related markers. Mechanistically, we demonstrated that E2F4 directly binds to the GPR176 promoter and transcriptionally activates its expression. Rescue experiments further validated that GPR176 overexpression abrogated the enhanced mitophagy and ferroptosis induced by E2F4 depletion. Collectively, our findings define an E2F4/GPR176/mitophagy axis that acts to suppress ferroptosis in EC, highlighting this pathway as a novel therapeutic target for inducing ferroptosis in EC intervention.
- Open Access
- 29 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Implication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy
Exosomes play a crucial role in triple-negative breast cancer (TNBC), influencing various aspects of tumor progression. Given the importance of exosomes in TNBC biology, we proposed a novel exosome-based model that was critically implicated in TNBC. Bulk and single-cell transcriptomics and genetic mutations of TNBC patients were curated for our study. Characteristic exosome genes were selected via LASSO analysis, with subsequent construction of an exosome-based model. The effectiveness in estimating clinical outcomes and treatment responses was then evaluated and validated. MDA-MB-231 and MDA-MB-468 TNBC cells were transiently transfected with FAM129B siRNAs, and cell proliferation and migration were measured via EdU and wound healing assays. The study determined 7 characteristic exosome genes for TNBC: ALCAM, FAM129B, GNB2, KRT6A, PGK1, SERPINE1, and THY1, which were utilized for defining the exosome-based gene signature. It was proven that the signature accurately estimated patient prognosis, and functioned as an independent prognostic predictor. High-risk tumors owned shorter overall survival time, but were suitable for treatment with docetaxel and several small-molecule agents (MK-0752, BRD-K33199242, IC-87114, fumonisin B1, ilomastat, GW-788388, afobazole, and batimastat). High- and low-risk tumors presented the distinct genetic mutation characteristics. The characteristic exosome genes were specifically expressed in the TNBC microenvironment components, indicating their involvement in modulating the microenvironment. High-risk individuals were inferred to better respond to immune checkpoint blockade (CD276, NRP1, TNFRSF4, TNFSF4 or CTLA4). Experimentally, inhibition of FAM129B effectively attenuated proliferative and aggressive phenotypes of TNBC cells. Collectively, our findings proposed the exosome-based gene signature for accurate estimation of clinical outcomes and assisting in individually tailoring therapies in TNBC as well as discovered FAM129B as a potential therapeutic target.
- 29 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-16
Open AccessImplication of an exosome-based gene signature for estimating clinical outcomes of triple-negative breast cancer and assisting in individualized therapy
Exosomes play a crucial role in triple-negative breast cancer (TNBC), influencing various aspects of tumor progression. Given the importance of exosomes in TNBC biology, we proposed a novel exosome-based model that was critically implicated in TNBC. Bulk and single-cell transcriptomics and genetic mutations of TNBC patients were curated for our study. Characteristic exosome genes were selected via LASSO analysis, with subsequent construction of an exosome-based model. The effectiveness in estimating clinical outcomes and treatment responses was then evaluated and validated. MDA-MB-231 and MDA-MB-468 TNBC cells were transiently transfected with FAM129B siRNAs, and cell proliferation and migration were measured via EdU and wound healing assays. The study determined 7 characteristic exosome genes for TNBC: ALCAM, FAM129B, GNB2, KRT6A, PGK1, SERPINE1, and THY1, which were utilized for defining the exosome-based gene signature. It was proven that the signature accurately estimated patient prognosis, and functioned as an independent prognostic predictor. High-risk tumors owned shorter overall survival time, but were suitable for treatment with docetaxel and several small-molecule agents (MK-0752, BRD-K33199242, IC-87114, fumonisin B1, ilomastat, GW-788388, afobazole, and batimastat). High- and low-risk tumors presented the distinct genetic mutation characteristics. The characteristic exosome genes were specifically expressed in the TNBC microenvironment components, indicating their involvement in modulating the microenvironment. High-risk individuals were inferred to better respond to immune checkpoint blockade (CD276, NRP1, TNFRSF4, TNFSF4 or CTLA4). Experimentally, inhibition of FAM129B effectively attenuated proliferative and aggressive phenotypes of TNBC cells. Collectively, our findings proposed the exosome-based gene signature for accurate estimation of clinical outcomes and assisting in individually tailoring therapies in TNBC as well as discovered FAM129B as a potential therapeutic target.
- 25 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 329, 147910
Integrative single-cell and bulk RNA sequencing of lactate metabolism identifies PDP-1 as a prognostic biomarker in breast cancer
- 25 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 329, 147910
Integrative single-cell and bulk RNA sequencing of lactate metabolism identifies PDP-1 as a prognostic biomarker in breast cancer
- 19 April 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (12) , 1177-1187
Unveiling the BRAF fusion structure variations through DNA and RNA sequencing
Background The detection of BRAF fusions by using next-generation sequencing (NGS) is essential for comprehensive analysis. Methods Data BRAF positive rearrangements from Chinese cancer patients were analyzed. DNA NGS was performed on FFPE samples, and RNA NGS was used to confirm fusion transcripts. Results BRAF fusions were identified in various cancers, predominantly glioma (87.8%). DNA NGS detected 371 BRAF fusion-positive samples, with 338 retaining the serine/threonine receptor tyrosine kinase domain (RTKD), divided into four groups: common (n = 254), rare (n = 66), intergenic (n = 7), and exonic (n = 11) fusions. Common fusions, mainly KIAA1549-BRAF, comprised the majority, with variations at introns 8, 9, and 10. Rare fusions and intergenic/exonic breakpoints displayed diverse structural patterns. RNA NGS verified transcriptional consistency in most samples from common fusions. However, various outcomes at the RNA level were found in other groups, involving mechanisms like alternative splicing, antisense rearrangement, and frameshift rearrangement. Additionally, 33 fusions lacked the RTKD, demonstrating significant structural diversity. Furthermore, 22 novel fusions were identified, which were distributed in tongue cancer, liver cancer, lung cancer, melanoma, brain cancer, and colon cancer. Conclusions Comprehensive molecular profiling and RNA sequencing are essential for accurate fusion detection, improving the design of NGS panels and aiding in the targeted therapy of BRAF fusion-positive cancers.
- 19 April 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (12) , 1177-1187
Unveiling the BRAF fusion structure variations through DNA and RNA sequencing
Background The detection of BRAF fusions by using next-generation sequencing (NGS) is essential for comprehensive analysis. Methods Data BRAF positive rearrangements from Chinese cancer patients were analyzed. DNA NGS was performed on FFPE samples, and RNA NGS was used to confirm fusion transcripts. Results BRAF fusions were identified in various cancers, predominantly glioma (87.8%). DNA NGS detected 371 BRAF fusion-positive samples, with 338 retaining the serine/threonine receptor tyrosine kinase domain (RTKD), divided into four groups: common (n = 254), rare (n = 66), intergenic (n = 7), and exonic (n = 11) fusions. Common fusions, mainly KIAA1549-BRAF, comprised the majority, with variations at introns 8, 9, and 10. Rare fusions and intergenic/exonic breakpoints displayed diverse structural patterns. RNA NGS verified transcriptional consistency in most samples from common fusions. However, various outcomes at the RNA level were found in other groups, involving mechanisms like alternative splicing, antisense rearrangement, and frameshift rearrangement. Additionally, 33 fusions lacked the RTKD, demonstrating significant structural diversity. Furthermore, 22 novel fusions were identified, which were distributed in tongue cancer, liver cancer, lung cancer, melanoma, brain cancer, and colon cancer. Conclusions Comprehensive molecular profiling and RNA sequencing are essential for accurate fusion detection, improving the design of NGS panels and aiding in the targeted therapy of BRAF fusion-positive cancers.
- RetractionOpen Access
- 20 January 2025
- Published by Impact Journals, LLC in Oncotarget
- Vol. 16 (1) , 680
Retraction: miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression
Https://doi.org/10.18632/oncotarget.28766 Guangyuan Song, Hongcheng Zhang, Chenlin Chen, Lijie Gong, Biao Chen, Shaoyun Zhao, Ji Shi, Ji Xu, Zaiyuan Ye
- 20 January 2025
- Published by Impact Journals, LLC in Oncotarget
- Vol. 16 (1) , 680
RetractionOpen AccessRetraction: miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression
Https://doi.org/10.18632/oncotarget.28766 Guangyuan Song, Hongcheng Zhang, Chenlin Chen, Lijie Gong, Biao Chen, Shaoyun Zhao, Ji Shi, Ji Xu, Zaiyuan Ye
- Open Access
- 10 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70191
Clinical relevance and druggability of sole reciprocal kinase fusions: A large‐scale study
Background: Building on our prior work that RNA alternative splicing modulates the druggability of kinase fusions, this study probes the clinical significance of sole reciprocal fusions. These rare genomic arrangements, despite lacking kinase domains at the DNA level, demonstrated potential RNA‐level druggability in sporadic cases from our prior research.Methods: Utilizing the large‐scale multicenter approach, we performed RNA sequencing and clinical follow‐up to evaluate a broad spectrum of kinase fusions, including ALK, ROS1, RET, BRAF, NTRK, MET, NRG1, and EGFR, in 1943 patients.Results: Our findings revealed 51 instances (2.57%) of sole reciprocal fusions, predominantly in lung (57%), colorectal (14%), and glioma (10%) cancers. Comparative analysis with an MSKCC cohort confirmed the prevalence in diverse cancer types and identified unique fusion partners and chromosomal locales. Cross‐validation through RNA‐NGS and FISH authenticated the existence of functional kinase domains in subsets including ALK, ROS1, RET, and BRAF, which correlated with positive clinical responses to targeted kinase inhibitors (KIs). Conversely, fusions involving EGFR, NRG1, and NTRK1/2/3 generated nonfunctional transcripts, suggesting the need for alternative therapeutic interventions.Conclusion: This inaugural multicenter study introduces a novel algorithm for detecting and treating sole reciprocal fusions in advanced cancers, expanding the patient population potentially amenable to KIs.
- 10 September 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (17) , e70191
Open AccessClinical relevance and druggability of sole reciprocal kinase fusions: A large‐scale study
Background: Building on our prior work that RNA alternative splicing modulates the druggability of kinase fusions, this study probes the clinical significance of sole reciprocal fusions. These rare genomic arrangements, despite lacking kinase domains at the DNA level, demonstrated potential RNA‐level druggability in sporadic cases from our prior research.Methods: Utilizing the large‐scale multicenter approach, we performed RNA sequencing and clinical follow‐up to evaluate a broad spectrum of kinase fusions, including ALK, ROS1, RET, BRAF, NTRK, MET, NRG1, and EGFR, in 1943 patients.Results: Our findings revealed 51 instances (2.57%) of sole reciprocal fusions, predominantly in lung (57%), colorectal (14%), and glioma (10%) cancers. Comparative analysis with an MSKCC cohort confirmed the prevalence in diverse cancer types and identified unique fusion partners and chromosomal locales. Cross‐validation through RNA‐NGS and FISH authenticated the existence of functional kinase domains in subsets including ALK, ROS1, RET, and BRAF, which correlated with positive clinical responses to targeted kinase inhibitors (KIs). Conversely, fusions involving EGFR, NRG1, and NTRK1/2/3 generated nonfunctional transcripts, suggesting the need for alternative therapeutic interventions.Conclusion: This inaugural multicenter study introduces a novel algorithm for detecting and treating sole reciprocal fusions in advanced cancers, expanding the patient population potentially amenable to KIs.
- Open Access
- 28 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 176957
WYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway
- 28 August 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 176957
Open AccessWYC-209 suppresses gastric cancer by down-regulating FGF18 via inactivating the STAT3 signaling pathway
- Open Access
- 4 January 2024
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 25 (1) , 2299288
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα
Gastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins and mRNA. RNA-seq and enrichment analyses were conducted for the differentially expressed genes and enriched biological processes and pathways. The rescue experiments were carried out for further validation. Besides, we constructed xenograft model to confirm the effect of WYC-209 in vivo. The dual-luciferase reporter and Chromatin immunoprecipitation were implemented to confirm the underlying mechanism. WYC-209 exerted excellent anti-cancer effects both in vitro and in vivo. Based on RNA-seq and enrichment analyses, we found that Wnt family member 4 (WNT4) was significantly down-regulated. More importantly, WNT4 overexpression breached the inhibitory effect of WYC-209 on GC progression. Mechanically, WYC-209 significantly promoted the binding between retinoic acid receptor α (RARα) and WNT4 promoter. WYC-209 exerts anti-tumor effects in GC by down-regulating the expression of WNT4 via RARα.
- 4 January 2024
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 25 (1) , 2299288
Open AccessWYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα
Gastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins and mRNA. RNA-seq and enrichment analyses were conducted for the differentially expressed genes and enriched biological processes and pathways. The rescue experiments were carried out for further validation. Besides, we constructed xenograft model to confirm the effect of WYC-209 in vivo. The dual-luciferase reporter and Chromatin immunoprecipitation were implemented to confirm the underlying mechanism. WYC-209 exerted excellent anti-cancer effects both in vitro and in vivo. Based on RNA-seq and enrichment analyses, we found that Wnt family member 4 (WNT4) was significantly down-regulated. More importantly, WNT4 overexpression breached the inhibitory effect of WYC-209 on GC progression. Mechanically, WYC-209 significantly promoted the binding between retinoic acid receptor α (RARα) and WNT4 promoter. WYC-209 exerts anti-tumor effects in GC by down-regulating the expression of WNT4 via RARα.